With 127 million new infections per year, Chlamydia trachomatis (CT) is one of the most common sexually transmitted infections (STIs).1
The majority of CT cases do not present with symptoms, making management of these bacterial infections a challenge. Undiagnosed and untreated, CT may result in complications that affect the urethra, cervix, uterus, and prostate. CT is also a known cause of infertility in women.2
Chlamydia is generally curable with existing, effective single-dose regimens of antibiotics, but has shown early signs of resistance.3 Diagnostic testing is an important strategic tool to help mitigate the impact of the disease, and stave off the potential consequences from a drug-resistant form of the bacteria.